Authors
Latest:
The Awake Craniotomy Presents Advantages in Resection of Eloquent Cortex Brain TumorsAwake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor and speech areas
Latest:
Dr Etame on How Patient Socioeconomic Status Affects Cancer CareArnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Latest:
Pursuing an Oncology Fellowship OverseasPostgraduate fellowship training is an essential cornerstone in medical training.
Latest:
Dr. Naik on Surgical Approaches in Patients With Breast CancerArpana M. Naik, MD, associate professor of surgery, Division of Surgical Oncology, School of Medicine, Oregeon Health and Science University, discusses surgical approaches in the treatment of patients with breast cancer.
Latest:
Dr Desai on the Implications of the CONTACT-03 Trial in RCCArpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.
Latest:
Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal TherapyArt Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
Latest:
Merging Community Practices With an Academic Cancer CenterConsolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Latest:
Dr. Hurria on Challenges Facing the Geriatric Population with Breast CancerArti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, discusses challenges facing geriatric patients with breast cancer.
Latest:
Dr. Loaiza-Bonilla on Trial of Left- and Right-Sided Colorectal CancerArturo Loaiza-Bonilla, MD, medical oncologist, specializing in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses a clinical trial focused on the differences between left- and right-sided tumors of colorectal cancer (CRC).
Latest:
Dr. Singh on Treatment for Patients With Uterine LeiomyosarcomaArun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses treatment for patients with uterine leiomyosarcoma.
Latest:
Ashani Weeraratna on Aging and MelanomaAshani Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, member, The Wistar Institute Melanoma Research Center, discusses a study examining the effects of aging on Wnt/ß-catenin signaling in melanoma.
Latest:
Dr. Chanan-Khan on Ibrutinib as Backbone of Treatment for CLLAsher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).
Latest:
Dr. Kamat on the Process of Meeting BCG Needs in Bladder CancerAshish M. Kamat, MD, discusses the process of meeting the needs for TICE Bacillus Calmette–Guérin in the treatment of patients with bladder cancer.
Latest:
Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLCAshish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Dr. Weiner on Radiotherapy Trials in NSCLCAshley A. Weiner, MD, PhD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses clinical trials that have investigated the use of radiotherapy in patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Rosko on Disparities Within Clinical Trials in Multiple MyelomaAshley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.
Latest:
Innovation in EHR Technology Drives Quality Oncology CareThe mantra in oncology over the last several years has revolved around how practices should deal with the myriad of challenges they face: new guidelines and regulations, lower reimbursement and a shift toward value-based patient care.
Latest:
Dr. Amin on CheckMate-214 Trial in RCCAsim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses the rationale for the pivotal CheckMate-214 trial in advanced renal cell carcinoma.
Latest:
It's Time to Integrate Complementary Medicine Discussions Into Oncology CareThe goal of increasing communications with the patient about all available and useful therapies contributes to better care of individuals and allows for continued education from oncology providers on potential risks and benefits of such therapies.
Latest:
Dr. Sacco on Ongoing Trials for Chemoradiation in Head and Neck CancerAssuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses ongoing trials investigating chemoradiation for patients with head and neck cancer.
Latest:
Dr. Hussein on the Evolution of Treatment in HCCAtif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.
Latest:
Dr Choudhury on Survival Advantages With AR Pathway Inhibitors in mHSPCAtish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.
Latest:
ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaThe novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.
Latest:
Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCCThe addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.
